×

2015's pharma buzzword? Immuno-oncology

5:50 AM ET Thu, 4 June 2015

Vamil Divan, senior analyst at Credit Suisse, explains why Bristol-Myers could benefit the most from the immune-oncology trend that's emerging in pharmaceuticals.